Sarcoma
Welcome,         Profile    Billing    Logout  
 515 Companies   302 Products   302 Products   167 Mechanisms of Action   1404 Trials   125634 News 


«12...15031504150515061507150815091510151115121513...15771578»
  • ||||||||||  Trial primary completion date:  Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma (clinicaltrials.gov) -  May 10, 2017   
    P=N/A,  N=3000, Recruiting, 
    Trial primary completion date: Jul 2017 --> Jul 2018 Trial primary completion date: Jun 2017 --> Jun 2018
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Enrollment change:  In Vivo Lung Perfusion for Pulmonary Metastases of Sarcoma (clinicaltrials.gov) -  May 8, 2017   
    P1,  N=11, Recruiting, 
    Trial primary completion date: Feb 2017 --> Apr 2016 N=18 --> 11
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Trial initiation date, PD(L)-1 Biomarker, IO biomarker:  AcS (clinicaltrials.gov) -  May 8, 2017   
    P2,  N=300, Not yet recruiting, 
    N=18 --> 11 Initiation date: Feb 2017 --> Jun 2017
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Enrollment open, Phase classification, Metastases:  Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial (clinicaltrials.gov) -  May 6, 2017   
    P2,  N=37, Recruiting, 
    Initiation date: Feb 2017 --> Jun 2017 Available --> Recruiting | Phase classification: PN/A --> P2
  • ||||||||||  Journal:  Heterogeneous Appearance of Central Nervous System Involvement in Malignant Mixed Müllerian Tumors. (Pubmed Central) -  May 6, 2017   
    As illustrated by the heterogeneous clinicopathologic features of our two cases as well as the reviewed literature, CNS metastasis of MMMTs is diagnostically challenging, shows a variable outcome, and thus requires individualized treatment. In the present cases and CNS metastases reported to date, a higher histologic ratio of sarcomatous to epithelial components portends a worse outcome.
  • ||||||||||  Journal:  Diseases of the tongue. (Pubmed Central) -  May 5, 2017   
    The oral cavity, along with the tongue, are sites of neoplasms, reactive processes, and infections, and may be a harbinger of systemic diseases. This review includes both common and rare diseases that occur on the tongue, including: vascular and lymphatic lesions (infantile hemangiomas and oral varices), reactive and inflammatory processes (hairy tongue, pigmented fungiform papillae of the tongue, benign migratory glossitis, and fissured tongue), infections (oral hairy leukoplakia, herpes simplex and varicella-zoster virus infections, human papillomavirus, and candidiasis), premalignant lesions (leukoplakia and erythroplakia), malignant lesions (squamous cell carcinoma, Kaposi sarcoma, and lymphoproliferative diseases), and signs of systemic disease (nutritional deficiency and systemic amyloidosis).
  • ||||||||||  Recentin (cediranib) / AstraZeneca
    Trial primary completion date, Monotherapy, Metastases:  Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov) -  May 4, 2017   
    P2,  N=70, Recruiting, 
    This review includes both common and rare diseases that occur on the tongue, including: vascular and lymphatic lesions (infantile hemangiomas and oral varices), reactive and inflammatory processes (hairy tongue, pigmented fungiform papillae of the tongue, benign migratory glossitis, and fissured tongue), infections (oral hairy leukoplakia, herpes simplex and varicella-zoster virus infections, human papillomavirus, and candidiasis), premalignant lesions (leukoplakia and erythroplakia), malignant lesions (squamous cell carcinoma, Kaposi sarcoma, and lymphoproliferative diseases), and signs of systemic disease (nutritional deficiency and systemic amyloidosis). Trial primary completion date: Apr 2017 --> Apr 2018
  • ||||||||||  trebananib (AMG 386) / Amgen
    Trial completion, Enrollment change, Trial primary completion date:  Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer (clinicaltrials.gov) -  May 4, 2017   
    P2,  N=35, Completed, 
    Trial primary completion date: Jan 2017 --> Jan 2018 Active, not recruiting --> Completed | N=55 --> 35 | Trial primary completion date: Mar 2016 --> Jul 2016
  • ||||||||||  Journal:  Endometrial adenosarcoma in the setting of a germline DICER1 mutation: A case report. (Pubmed Central) -  May 3, 2017   
    Active, not recruiting --> Completed | N=55 --> 35 | Trial primary completion date: Mar 2016 --> Jul 2016 •DICER1 mutations play a significant role in gynecologic malignancy.•DICER1 may be involved in the sarcomagenesis of endometrial adenosarcoma.•The knowledge of a genetic mutation can help clarify a patient's medical history.
  • ||||||||||  imatinib / Generic mfg.
    Trial completion:  Study to Evaluate Imatinib in Desmoid Tumors (clinicaltrials.gov) -  May 3, 2017   
    P2,  N=39, Completed, 
    •DICER1 mutations play a significant role in gynecologic malignancy.•DICER1 may be involved in the sarcomagenesis of endometrial adenosarcoma.•The knowledge of a genetic mutation can help clarify a patient's medical history. Active, not recruiting --> Completed
  • ||||||||||  Gilotrif (afatinib) / Boehringer Ingelheim
    Trial primary completion date, Monotherapy, Pan tumor:  Trial of Afatinib in Pediatric Tumours (clinicaltrials.gov) -  May 3, 2017   
    P1,  N=60, Recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Jun 2017 --> Feb 2019
  • ||||||||||  Enrollment closed:  A Study of Lymphoseek (clinicaltrials.gov) -  May 3, 2017   
    P2,  N=27, Active, not recruiting, 
    N=92 --> 200 | Trial primary completion date: Jun 2017 --> Aug 2019 | N=92 --> 200 | Trial primary completion date: Jun 2017 --> Aug 2019 Recruiting --> Active, not recruiting
  • ||||||||||  New trial:  Radiation Effects on Bone (clinicaltrials.gov) -  Apr 30, 2017   
    P=N/A,  N=50, Enrolling by invitation, 
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS
    Biomarker, Review, Journal:  Targeting the PD-1 pathway in pediatric solid tumors and brain tumors. (Pubmed Central) -  Apr 28, 2017   
    In this manuscript we review current strategies for targeting the PD-1 pathway, highlighting putative biomarkers and the rationale for investigation of these drugs to treat common pediatric tumors such as sarcoma, neuroblastoma, and high-grade glioma. We summarize the completed and ongoing clinical trial data available, and suggest potential applications for further study.
  • ||||||||||  Recentin (cediranib) / AstraZeneca
    Trial completion, Trial primary completion date, Combination therapy:  Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) -  Apr 28, 2017   
    P1/2,  N=46, Completed, 
    We summarize the completed and ongoing clinical trial data available, and suggest potential applications for further study. Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> Apr 2014
  • ||||||||||  cabazitaxel / Generic mfg.
    Enrollment open, Trial primary completion date, Metastases:  cabazL06470: Ph II Cabazitaxel DD Liposarcoma (clinicaltrials.gov) -  Apr 28, 2017   
    P2,  N=100, Recruiting, 
    N=36 --> 78 | Trial primary completion date: Dec 2016 --> Dec 2017 Suspended --> Recruiting | Trial primary completion date: Feb 2017 --> Feb 2019
  • ||||||||||  Tecelra (afamitresgene autoleucel) / Adaptimmune
    New P1 trial, Pan tumor:  MAGE-A4? (clinicaltrials.gov) -  Apr 27, 2017   
    P1,  N=32, Not yet recruiting, 
  • ||||||||||  methotrexate IV / Generic mfg.
    Trial completion, Enrollment change, Trial primary completion date, HEOR, Cost effectiveness:  Outpatient Administration of High Dose Methotrexate (HD MTX) in Patients With Osteosarcoma (clinicaltrials.gov) -  Apr 27, 2017   
    P3,  N=6, Completed, 
    Only LG-ESS might respond to progestins or aromatase inhibitors. Recruiting --> Completed | N=12 --> 6 | Trial primary completion date: Feb 2017 --> Oct 2016